Open AccessImplementation of a Multicenter Biobanking Collaboration for Next‐Generation Sequencing‐Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies
Author(s) -
Bins Sander,
Cirkel Geert A.,
GadellaaVan Hooijdonk Christa G.,
Weeber Fleur,
Numan Isaac J.,
Bruggink Annette H.,
van Diest Paul J.,
Willems Stefan M.,
Veldhuis Wouter B.,
van den Heuvel Michel M.,
de Knegt Rob J.,
Koudijs Marco J.,
van Werkhoven Erik,
Mathijssen Ron H.J.,
Cuppen Edwin,
Sleijfer Stefan,
Schellens Jan H.M.,
Voest Emile E.,
Langenberg Marlies H.G.,
de Jonge Maja J.A.,
Steeghs Neeltje,
Lolkema Martijn P.
Publication year - 2017
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2016-0085
Subject(s) - medicine , biopsy , cancer , biomarker discovery , biomarker , lung cancer , oncology , pathology , proteomics , gene , biochemistry , chemistry
Background The discovery of novel biomarkers that predict treatment response in advanced cancer patients requires acquisition of high‐quality tumor samples. As cancer evolves over time, tissue is ideally obtained before the start of each treatment. Preferably, samples are freshly frozen to allow analysis by next‐generation DNA/RNA sequencing (NGS) but also for making other emerging systematic techniques such as proteomics and metabolomics possible. Here, we describe the first 469 image‐guided biopsies collected in a large collaboration in The Netherlands (Center for Personalized Cancer Treatment) and show the utility of these specimens for NGS analysis. Patients and Methods Image‐guided tumor biopsies were performed in advanced cancer patients. Samples were fresh frozen, vital tumor cellularity was estimated, and DNA was isolated after macrodissection of tumor‐rich areas. Safety of the image‐guided biopsy procedures was assessed by reporting of serious adverse events within 14 days after the biopsy procedure. Results Biopsy procedures were generally well tolerated. Major complications occurred in 2.1%, most frequently consisting of pain. In 7.3% of the percutaneous lung biopsies, pneumothorax requiring drainage occurred. The majority of samples (81%) contained a vital tumor percentage of at least 30%, from which at least 500 ng DNA could be isolated in 91%. Given our preset criteria, 74% of samples were of sufficient quality for biomarker discovery. The NGS results in this cohort were in line with those in other groups. Conclusion Image‐guided biopsy procedures for biomarker discovery to enable personalized cancer treatment are safe and feasible and yield a highly valuable biobank. Implications for Practice This study shows that it is safe to perform image‐guided biopsy procedures to obtain fresh frozen tumor samples and that it is feasible to use these biopsies for biomarker discovery purposes in a Dutch multicenter collaboration. From the majority of the samples, sufficient DNA could be yielded to perform next‐generation sequencing. These results indicate that the way is paved for consortia to prospectively collect fresh frozen tumor tissue.